SECOND TEAM Geoffrey Meacham J.P. Morgan
Geoffrey Meacham lands in second place for a fourth consecutive year. The J.P. Morgan researcher “understands the potential of products in development and uses that knowledge to make winning recommendations,” says one money manager. Case in point: In March the analyst advised clients to overweight Pharmasset, a clinical-stage pharmaceuticals company headquartered in Princeton, New Jersey. Meacham was impressed with the company’s PSI-7977 drug being developed to treat hepatitis C. By the end of August, the stock had nearly doubled in price, from $66.24 to $131.53. During the same period the sector advanced just 6.9 percent.